Drug interactions and the pharmacist: Focus on Everolimus;Interacciones Farmacológicas y el Farmacéutico: Everolimus

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages 1055-1063

  Grabowsky, Jennifer A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ATAZANAVIR; BORTEZOMIB; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DOXORUBICIN; ERYTHROMYCIN; ETOPOSIDE; EVEROLIMUS; EXEMESTANE; GRAPEFRUIT EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LETROZOLE; MULTIDRUG RESISTANCE PROTEIN; NEFAZODONE; RIFAMPICIN; SORAFENIB; SOUR ORANGE EXTRACT; SUNITINIB; TRIMETHOPRIM; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL; VINCRISTINE;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG TREATMENT FAILURE; FOOD DRUG INTERACTION; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; KIDNEY CARCINOMA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT SAFETY; PHARMACIST; POSTMENOPAUSE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HERB-DRUG INTERACTIONS; HUMANS; PHARMACISTS; SIROLIMUS;

EID: 84880051527     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R769     Document Type: Article

References (45)

1. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007;99:592-600.
2. Riechelmann RP, del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol 2009;20:1907-12.
3. Hanigan MH, la Cruz BL, Thompson DM, Farmer KC, Medina PJ. Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation. J Oncol Pharmacy Pract 2008;14:123-30.
4. Lebwohl D, Thomas G, Lane HA, et al. Research and innovation in the development of everolimus for oncology. Exp Opin Drug Discovery 2011;6:323-38.
5. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10:8421-5.
6. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, deGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18:1323-8.
7. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12: 5165-73.
8. Margariti N, Fox SB, Bottini A, Generali D. "Overcoming breast cancer drug resistance with mTOR inhibitors. " Could it be a myth or a real possibility in the short-term future? Breast Cancer Res Treat 2011;128:599-606.
9. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90.
10. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010;10(suppl 3):S59-65.
11. Prescribing information. Afinitor (everolimus). Novartis Pharmaceuticals Corporation, East Hanover, NJ; August 2012. http://www.pharma.us. novartis.com/product/pi/pdf/afinitor.pdf (accessed 2013 Mar 13).
12. Ricart AD, Sarantopoulos J, Calvo E, et al. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study. Clin Cancer Res 2009;15:3866-71.
13. Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008;29:2162-8.
14. Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008;14:4200-5.
15. Suzuki Y, Sugai T, Fukui N, et al. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol (Oxf) 2011;25:908-14.
16. van der Bol JM, Mathijssen RH, Loos WJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007;25:2719-26.
17. Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004;10:7031-42.
18. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-28.
19. Huang JJ, Li ZM, Huang Y, et al. Schedule-dependent inhibition of Tcell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs. Invest New Drugs 2012;30:223-5.
20. O'Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-95.
21. Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002;36:981-5.
22. Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999;27:627-32.
23. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002;22:154-9.
24. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 1999;36:233-54.
25. Veering BT, Burm AG, Souverijn JH, Serree JM, Spierdijk J. The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol 1990;29:201-6.
26. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95.
27. O'Reilly T, McSheehy PM, Kawai R, et al. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol 2010;65:625-39.
28. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr 2001;33:453-8.
29. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007;12:927-41.
30. Chang GW, Kam PC. The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia 1999;54:42-50.
31. Gu J, Weng Y, Zhang QY, et al. Liver-specific deletion of the NADPHcytochrome P450 reductase gene: impact on plasma cholesterol homeo-stasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003;278:25895-901.
32. Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009;37:2087-94.
33. Wolters Kluwer Health. Lexicomp. http://www.lexi.com/ (accessed 2013 Mar 12).
34. Picard N, Rouguieg-Malki K, Kamar N, Rostaing L, Marquet P. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation 2011;91:652-6.
35. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005;45:514-8.
36. Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 2006;27:421-6.
37. Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ. Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc 2013;88:139-48.
38. Nowack R. Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's wort, and beyond! Nephrology 2008;13:337-47.
39. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997;25:1228-33.
40. Hidaka M, Fujita K, Ogikubo T, et al. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug Metab Dispos 2004;32:581-3.
41. Shen J, Andersen R, Albert PS, et al. Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2002;2:8.
42. Mansky PJ, Straus SE. St. John's wort: more implications for cancer patients. J Natl Cancer Inst 2002;94:1187-8.
43. Hennessy M, Kelleher D, Spiers JP, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82.
44. Matheny CJ, Ali RY, Yang X, Pollack GM. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos 2004;32:1008-14.
45. Mathijssen RH, Verweij J, de Bruijne J, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-9.